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Abstract Aretrospective cohort using pharmacy andmedical claimswas analysed to determinewhether the di¡er-
ences in e⁄cacy of various inhaled corticosteroids demonstrated in clinical trials lead to di¡erences in costs of care ob-
served in clinical practice. Subjects that had an ICD-9 (493.XX) code for asthma and a new pharmacy claim for inhaled
£uticasone propionate 44 mcg (FP), beclomethasone dipropionate (BDP), triamcinolone acetonide (TAA), budesonide
(BUD) or £unisolide (FLU) were identi¢ed and followed for 12 months. Annual asthma care charges (pharmacy and
medical) over the12-month observation period were signi¢cantly (Po0?03) higher in patients treated with BDP,TAA,
BUDand FLUcomparedto FP, 24%, 27%,34% and 45% respectively.In addition, patients treatedwith BDP,TAA, and FLU
were associated with signi¢cantly (P0?005) higher total healthcare (asthma  non-asthma) charges compared to
patients on FP, 53%,46% and 39% respectively. Asthma care and total healthcare charges remained lower for FP after
including FP110mcgand excludingpatientswhowere extreme costoutliers (72 SD fromthemean) in a univariate sensi-
tivity analysis.This analysis supports recent randomized control trials that FP o¡ers a superior e⁄cacy pro¢le at lower
asthma care aswell as totalhealthcare charges compared to other inhaled corticosteroids.r2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1185, available online at http://www.idealibrary.comon
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Asthma care in the United States accounts for an esti-
mated $US12?6 billion annually with approximately $US
7?4 billion being direct medical costs. Of these direct
medical expenditures approximately 40% are related to
hospital care [emergency department (ED) or hospital
encounters] (1, 2). Several studies have demonstrated
that appropriate pharmacological intervention can re-
ducemortality and decrease hospitalization and EDutili-
zation in peoplewith asthma (3^6).
The National Asthma Education and Prevention
Program’s Expert Panel Report 2 (EPR 2) ‘Guidelines for
the Diagnosis and Management of Asthma’ recommends
inhaled corticosteroids as theprimary treatment for the
management of persistent asthma (7).The EPR 2 estab-
lished criteria for starting and adjusting maintenance
medications based on level of asthma severity. Inhaled
corticosteroids are considered the most e¡ective long-
term control therapy for persistent asthma for all levelsReceived 26 April 2000, accepted in revised form 6 August 2001and
published online17 October 2001.
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Sponsoredby GlaxoSmithKline, Inc.of severity. In addition, the EPR 2 recognized that inhaled
corticosteroids potency varies on a microgram basis.
Since the publication of the EPR 2 in 1997, numerous
clinical comparisons have demonstrated relative clinical
di¡erences between the marketed inhaled corticoster-
oids (8^15). In the majority of these studies, as well as
studies in patients with rhinitis (15), a new generation in-
haled corticosteroid, £uticasonepropionate (FP), has de-
monstrated safety and e⁄cacy advantages compared to
the older generation ICS [beclomethasone (BDP), bude-
sonide (BUD), triamcinolone (TAA) and £unisolide
(FLU)] (9,16^18).While no single approach to the assess-
ment of potency of ICS relative to both safety and e⁄-
cacy has been established, the EPR 2 ranks
FP4BUD=BDP4TAA4FLU.
Randomized clinical trials are the highest level of
evidence used to establish comparative di¡erences in ef-
¢cacy.However, therestricted selection criteria of a clin-
ical trial and the structured protocol with inducements
for maintaining compliance and frequent physician con-
tact may decrease the generalizability of the results to
clinical practice. In addition, clinical trials tend to be of
short duration, usually  12 weeks. This short duration
as well as the restrictive entry criteria limits cost-
e⁄cacy analyses derived from these studies. Retrospec-
tive cohort studies using linked administrative medical
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andvalidate the data fromclinical cost-e⁄cacy trials (19^
22). Retrospective studies complement the e⁄cacy
studies with long term cost data that are generated in
clinical practice settings.These cohort analyses using ad-
ministrative claims may utilize large patient populations
not feasible in clinical trials andmaybetter re£ect actual
clinical practice conditions (19).For these reasons, retro-
spective database analysis may be more applicable for
cost comparison investigations (19^24).
The objective of this study was to determinewhether
the di¡erences between the inhaled corticosteroids
noted in laboratory and clinical e⁄cacy trials are trans-
lated into di¡erences in overall asthma care charges as
measured by the e¡ect that these treatments have on
direct medical and pharmacy utilization. The objective
of this study is to compare associated treatment charges
for subjects taking ICS for the treatment of asthma in a
managed care environment. Speci¢cally, FP 44mcg was
compared to older generation inhaled corticosteroids;
BDP, BUD,TAA and FLU, in patients who did not have a
pharmacyclaim for inhaledcorticosteroid or leukotriene
modi¢ers for 6months prior to their ¢rst ICS pharmacy
claim. Total asthma care charges and total healthcare
charges were the outcomes of interest. These charges
included asthma and non-asthma related pharmacy and
medical charges.
METHODS
This was a retrospective administrative data analysis
utilizing physician, hospital and pharmacy claims con-
tained within the Pharmetrics Integrated Outcomess
database.The Pharmetrics Integrated Outcomess data-
base contains medical and pharmaceutical claims from
over 20 managed healthcare plans across the United
States, encompassing over10 million lives for this period
of study. For the purposes of this analysis, patients from
only one plan were included in the study, as it was the
only plan that covered the entire study period and
included information on all ¢ve inhaled corticosteroids
of interest.
Patient Identi¢cation
Patients aged 12^64 years were included if they had an
International Classi¢cation of Disease, 9th Revision-
Clinical Modi¢cation code (ICD-9-CM) for asthma
(ICD-9-CM: 493.XX) and had continuous enrollment in
a healthcare plan for at least 18 consecutive months
around the index event.The index event was de¢ned as
an initial pharmacy claim for one of ¢ve inhaled corticos-
teroids: £uticasone propionate 44mcg (FP), budesonide
(BUD), triamcinolone (TAA), £unisolide FLU) or
beclomethasone BDP. To ensure that the indexprescription was in fact the ¢rst claim for an inhaled
corticosteroid (ICS), patients were required to have a
6-month ICS-free period prior to the index date;
they were further required to have at least two
claims for the same agent in the 12 months following
the index event. In addition, these patients could not
have any leukotriene modi¢er (LTM) or salmeterol in
the 6-month pre-index baseline period. Patients with
cystic ¢brosis (ICD-9-CM: 277) or chronic obstructive
pulmonary disease (ICD9-CM: 491, 492, 493.2 or 496)
were excluded from the study. Those with pharmacy
claims for long-acting b-agonists or leukotriene modi-
¢ers, and patients over 45 years with more than one
claim for ipratropium bromide were also excluded from
the analysis.
This was an intent-to-treat analysis, thus patients who
were switched to alternate therapies or thosewith over-
lapping claims of more than one ICS were analysed for
the entire 12-month post-index period as a member of
their original cohort. Because of the relative potency of
FP, the base case analysis for this study was the compar-
ison of FP 44 mcg to any strength of TAA, BDP, BUD or
FLU.
Descriptivemeasures
Asthma-speci¢c medical and pharmacy claims were
captured for the 6-month pre-index period and the
12-month post-index period. Relevant medical encoun-
ters included: asthma-related hospitalizations, emer-
gency department visits, outpatient visits and use of
ancillary services. Charges associated with medical and
pharmacy claims were calculated, as were total asthma-
related charges.Overallmedical chargeswere also calcu-
lated for pharmacy and medical encounters. Data
captured in the 6-monthpre-index periodwereused ex-
clusively to risk adjust the cohorts. Since the pre- and
post-periods were of di¡erent lengths, a pre ^post
univariate analysis was not performed.
A number of patient demographics were measured
and subsequently used to adjust for di¡erences between
the cohorts using multivariate analyses. These include
known determinants of increased medical utilization in-
cludingpatient age, gender and thepresence of comorbid
medical conditions.We furthermeasured the use of oral
steroid and short-actingb-agonists as a proxy for disease
severity and these were also adjusted for in the multi-
variatemodels.
Analysis
Patient demographics for BDP,TAA, FLU and BUDwere
each independently compared to the reference cohort
FP using t-tests for continuous variables and tests of
proportions for dichotomous variables. Wilcoxon rank
994 RESPIRATORYMEDICINEsum tests were used to assess di¡erences in unadjusted
charges.To address di¡erences in treatment cohorts that
may have confounded any inter-group comparisons,
multiple log-linear regression analysis was used to exam-
ine the e¡ect of independent variables on the post-index
(log-transformed) asthma-speci¢c and total healthcare
charges. Covariates included in the regression models
were age, age squared, gender, pre-index asthma speci¢c
charges, co-morbid respiratory conditions, other
co-morbidities (e.g. diabetes), and pre-index use of
concomitant of oral corticosteroids and short-acting
b-agonists. Adjustedmean chargeswere calculatedusing
least squaresmean andDuan’s retransformationmethod
are reported (25). All analyses were conducted using
SAS Version 7?0 (26), and tests of signi¢cance were
performed at an a priori ao0?05.
Sensitivity analysis
Because FP110mcg is used as an alternative to FP 44mcg
using fewer inhalations per day, we assessed the impact
of including FP 110mcg on the total and asthma-speci¢c
economic endpoints. Furthermore, an additional com-
parison of FP 44/110 patients to the other cohorts with
extreme outliers (72SD from the mean) removed from
the sample was conducted to ensure that the original
results observedwere not due to a few outliers skewing
the data.
RESULTS
Demographics and baseline utilization
A total of 1956 patients met the inclusion/exclusion
criteria.Of these,131were identi¢ed as new users of FP
44mcg, 598 as newusers of BDP,91as newusers of BUD,TABLE 1. Patientdemographics
Parameter FP
Total (n) 131
Average age, yrs (SD) 39?9 (710?4)
Female (%) 70?2%
Co-morbidities*
Upper respiratory infection 38 (29%)
Hypertension 8 (6?1%)
Depression 9 (6?9%)
Lower respiratory infection 3 (2?3%)
Diabetes 2 (1?5%)
Meanmonthly asthma charges ($US) 49?07
Meanmonthly totalhealthcare charges ($US) 325?95
FP:£uticasone 44mcg;BDP:beclomethasone;TA:triamcinolon
*Less prevalent (1%) co-morbid conditions: coronary artery d
disease.967 as new users of TAA and169 new users of FLU.Daily
dosage information was not available from the database
and could not be determined. Baseline demographic
characteristics were similar between cohorts (Table 1).
Mean age ranged from 40 years in the FP 44mcg cohort
to 44 years in the FLUcohort.Each group hadmore wo-
men thanmen however, gender distributionwas not sig-
ni¢cantlydi¡erentbetween each comparison cohort and
the FPcohort.Meanper patientmonthly asthma-related
treatment charges and total healthcare charges are re-
ported inTable1.Meanmonthly baseline charges di¡ered
between the comparison groups and FP, with BUD
having the greatest baseline mean monthly asthma
charges of $66?25 while TAA had the lowest
baseline mean asthma charges of $45?96. In addition,
BUD had the largest mean monthly total healthcare
charges of $465?64 while FLU had the lowest mean
monthly total charges of $186?45. These baseline
di¡erences in charges, asthma medication utilization
and comorbidities were included as covariates in the re-
gressionmodel.
All pre-index (baseline) and post-index (treatment)
charges related to the treatment of asthma for each
inhaled corticosteroids are reported in Tables 2 and 3.
Compared to the 6-month pre-index baseline period,
totalmonthly asthma charges in the12-monthpost-index
treatment period increased forTAA, BDP and FLU and
decreased for FP and BUD. As expected, the unadjusted
asthma medication charges increased in all ¢ve inhaled
corticosteroid groups while hospitalization charges
decreased in each group except for TAA which had a
slight increase of 8% in inpatientcare charges.This obser-
vation re£ects what would be expected in a population
of untreated asthmatics who subsequently receive anti-
in£ammatory treatment. However compared to the
monthly pre-period charges, FP had the largest decreaseBDP TAA FLU BUD
598 967 169 91
40?8 (711?6) 41?5 (711?2) 44?0 (711?4) 41?3 (711?3)
72?1% 72?1% 71?0% 70?3%
135 (22?6%) 218 (22?5%) 26 (15?4%) 26 (28?6%)
50 (8?4%) 93 (9?6%) 11 (6?5%) 14 (15?4%)
19 (3?2%) 38 (3?9%) 5 (6%) 8 (8?8%)
13 (2?2%) 30 (3?1%) 7 (4?1%) 8 (8?8%)
19 (3?2%) 33 (3?4%) 2 (1?2%) 5 (5?5%)
56?85 45?97 48?34 66?25
281?00 265?74 186?45 465.64
e;BUD:budesonide;FLU:£unisolide.
isease, congestive heart failure, sepsis and peripheral vascular
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FLN and BUD,13%, 57% and 57% decreases respectively.
In addition FP was observed to have the smallest
increase in asthma related pharmacy charges,172%, rela-
tive to BDP, TAA, FLN and BUD, 247%, 321%, 301% and
270% increases respectively. This overall decrease in
inpatient care charges and the lower increase inmonthly
medication charges observed with FP 44 may account
for the lower unadjusted di¡erences in monthly asthma
expenditures that favored the FP 44 cohort.
Treatment period utilization by cohort
Figure1presents the risk adjustedmeanmonthly asthma
care and total healthcare charges for each cohort during
the 12-month treatment period. From the regression
model, compared to FP, all the other inhaled cortico-
steroids were associated with signi¢cantly higher
(Po0?03) asthma care charges during the 12-month
treatment period (Table 4). Beclomethasone patients
were associated with 24% higher asthma care charges,
BUD patients were associated with 34% higher asthmaTABLE 2: Pre-indexunadjustedmeanmonthly asthma-speci¢c
Variable FP (n= 131) BDP (n= 598
ER ($US) 1?11 1?63
Inpatientz ($US) 28?52 37?74
Ancillary8 ($US) 0?56 1?48
Outpatient ($US) 13?44 10?29
Asthmamedications ($US) 5?44 5?71
Total asthma ($US) 49?07 56?85
*Totalper personmonthlycharges over the 6-month pre-per
zIncludes surgical, facility, management and ancillary.
8Non-clinician.
FP:£uticasone 44 mcg;BDP:beclomethasone;TAA:triamcinolon
TABLE 3. Post-indexunadjustedmeanmonthly asthma-speci¢c
Variable FP (n= 131) BDP (n= 598
ER ($US) 0?61 0?94
Inpatient z($US) 10?95 32?78
Ancillary 8($US) 0?43 0?30
Outpatient ($US) 8?57 9?86
Asthmamedications ($US) 14?84 19?84
Averagemonthly ($US) 35?40 63?73
*Totalpre personmonthlycharges over12-monthpost-period
zIncludes surgical, facility, management and ancillary.
8Non-clinician.
FP:£uticasone 44 mcg;BDP:beclomethasone;TAA:triamcinoloncharges, TAA patients were associated with 45% higher
asthma care charges and FLU patients were associated
with 45% higher asthma charges compared to FP. In addi-
tion, BDP, TAA and FLU were associated with signi¢-
cantly (P0?005) higher total healthcare charges, 53%,
43% and 39% respectively, compared to FP.However, to-
tal healthcare chargeswere not signi¢cantly di¡erent for
BUD compared to FP.
A sensitivity analysis was performed comparing
mean total asthma care expenditures for patients
receiving FP 44mcg or FP 110mcg as compared to
new users of all other inhaled corticosteroids
(Table 5). Patients treated with FP (44mcg or 110mcg)
continued to realize signi¢cantly lower asthma care
charges as compared to any competing inhaled
corticosteroid (Po0?04). Speci¢cally, new users of FP
(44mcg or110mcg) had between16% and 43% lower to-
tal asthma care expenditures after controlling for co-
morbid medical conditions, pre-index medication use
and other patient demographics. In addition, asthma
charges continued to be signi¢cantly lower with FP44/
110 after the removal of extreme outliners (72SD from
themean).treatmentcharges*
) TAA (n= 967) FLU (n= 169) BUD (n= 91)
1?14 1?29 0?56
31?72 31?80 41?34
0?70 0?69 0?48
7?24 5?96 17?77
5?16 8?60 6?09
45?96 48?34 66?25
iod.
e;BUD:budesonide;FLU:£unisolide.
treatmentcharges*
) TAA (n= 967) FLU (n= 169) BUD (n= 91)
0?95 1?74 0?21
34?37 13?83 17?91
0?99 0?63 0?56
9?37 8?88 9?33
21?72 34?47 22?58
67?40 59?54 50?59
.
e;BUD:budesonide;FLU:£unisolide.
FIG. 1. Risk adjusted mean monthly asthma (&) and total healthcare charges (&) during the 12-month treatment period. *Least
squaresmean adjusting for age, gender, pre-index healthcare charges, co-morbid respiratory conditions, other co-morbidities (such
as diabetes), and pre-index concomitant asthmamedications (short actino b-agonists, oral corticosteroids and theophylline).Po0?03
for FP vs.BDP,TAA,FLUand BUD for asthma care charges, P0?005 for FP vs.BDP,TAA and FLU for totalheatlhcare charges.
TABLE 4. Parameter estimates of post-index asthma-speci¢c charges:FP 44mcg vs. individual inhaled corticosteroids
Variable Reference b-coe⁄cient Standard error P
Intercept 5?09 0?32 0?0001
Beclomethasone Fluticasone 44 mcg 0?24 0?11 0?0233
Budesonide Fluticasone 44 mcg 0?34 0?15 0?0248
Flunisolide Fluticasone 44 mcg 0?45 0?13 0?0005
Triamcinolone Fluticasone 44 mcg 0?27 0?10 0?0087
Member age 0?010 0?015 0?5073
Use of oral corticosteroids or theophylline
(pre-index)*
No oral corticosteroid
or theophylline
0?15 0?055 0?0081
Use of oral corticosteroids and theophylline
(pre-index)*
No oral corticosteroid
or theophylline
0?62 0?10 0?0001
1Albuterolprescription (pre-index) No albuteroluse ÿ0.29 0?068 0?0001
 2 Albuterolprescriptions (pre-index) No albuteroluse 0?30 0?061 0?0001
Logasthma charges (pre-index) ÿ0?024 0?011 0?0224
Othernon-signi¢cantmodel inputs included: age squared and individual co-morbidities (seeTable1).
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The results of this clinical administrative claims analysis
showed consistently lower asthma care charges for FP
compared to all other inhaled corticosteroids.The ¢nd-
ings remained even after including FP 110 mcg and
excluding extreme cost outliers. In addition, these lower
charges were also observed in total healthcare expendi-
tures (asthma+ non-asthma charges) when compared to
BDP,TAA and FLU.
Previous clinical trials have demonstrated that FP is
associatedwithbetter clinical outcomes and lower treat-
ment related charges than alternative inhaled corticos-
teroids (7^10,13). The decision to use new therapeutic
agents is usuallybased on potentially greater clinical ben-e¢t.Comparative clinical trialswith the inhaled corticos-
teroids have con¢rmed that these inhaled
corticosteroids do not produce the same clinical e¡ect
on a microgram to microgram basis (7^13). The di¡er-
ences in charges seen in this observational studymay be
related to not only the di¡erences in how these inhaled
steroids are used but suggest that the more potent
inhaled corticosteroids may result in better clinical out-
comes and reduced healthcare costs due to their im-
proved safety and e⁄cacy pro¢les.
Our results are consistent with previous estimates of
the impact of inhaled corticosteroid use on the cost of
asthma care. Ozminkowski et al., analysing Marketscan
data, reported that patients treated with inhaled corti-
costeroids had increases in asthma related costs but
TABLE 5. Results of sensitivity analysis on asthma-related charges*
Model BDP TAA FLU BUD
bw P-value bw P-value b w P-value bw P-value
FP 44mcg (base case) 0?24 0?0233 0?27 0?0087 0?45 0?0005 0?34 0?0248
FP 44/110 0?15 0?0275 0?18 0?0048 0?38 0?0002 0?27 0?0374
FP 44/110 (outliers removedz) 0?16 0?0181 0?20 0?0017 0?43 0?0001 0?35 0?0058
*b-coe⁄cientof variable (referent for all cohorts = FP) for log-linear regression of post period asthma-speci¢c charges.
wb-coe⁄cient = per cent increase in costs related to the drug of interestcompared to FP.
zOutliers =72SD fromthemean.
b= b-coe⁄cient.
FP:£uticasone;BDP:beclomethasone;TAA:triamcinolone;BUD:budesonide;FLU:£unisolide.
COSTCOMPARISONOFINHALEDCORTICOSTEROIDS 997reductions in overall healthcare costs (27). Lozano et al.
reported from an administrative claims analysis that chil-
dren with asthma had greater non-asthma related costs
than childrenwithout a chronic illness (28).This suggests
that the costs associated with asthma go beyond what
usually is de¢ned by an asthma ICD-9 code or asthma
medication claim.Retrospective studies using claimsdata
looking at the cost of asthma may take this into account
by looking at all medical costs as well as the e¡ect that
asthma may have on the non-asthma related healthcare
of the patient (28). Our study found that FP use was
associated with lower asthma care charges as well as
lower total healthcare charges compared to the other
inhaled corticosteroids.This ¢nding is important to third
party payers as well as physicians who are concerned
about the cost of asthma care.
Retrospective cohort studies using claims data have
signi¢cant limitations. Reasons for physicians’ choice of
medication or severity of disease can not be determined
using administrative claims. Multiple covariate analyses
controlling fordi¡erence inbaseline demographics;base-
line costs, comorbid conditions, age, gender, andbaseline
use of asthma medication is a widely used technique in
administrative claims-based research and is generally
accepted as a reliable method for adjusting for disease
severity (19^22). However, other factors not accounted
formay a¡ect outcomes such asmisdiagnosis or misclas-
si¢cation of disease. If misclassi¢cation did occur, it
should be equal between study groups. In addition, the
results from retrospective cohort studies show the
associations between drug and outcomes although caus-
ality is di⁄cult to determine. Despite these limitations,
these data provide important information on the overall
cost of care associated with the use of the medications
occurring in clinical practice.
The reluctance to use medications because of their
acquisition costs is widespread and is seen in managed
care plans that look at cost from silo perspectives and
not from the total healthcare perspective. In this study
the addition of all these inhaledcorticosteroids increasedasthma medication costs as expected. Based on average
wholesale price of the recommended starting doses, the
inhaled corticosteroid studied are comparably priced
(range of $US 1?56^$US1?85) except for FLU which has
the highest average wholesale price of $US 2?53 per day
(29). In this analysis FP 44mcgwas associatedwith lower
adjusted asthma care (pharmacy and medical) charges
compared to BDP, BUD, TAA and FLU. In addition, FP
44mcg was also associated with lower asthma and non-
asthma-related healthcare charges compared to BDP,
TAA and FLU. This would translate into a yearly per
patient savings between $199^$433 for asthma care
charges and $1188^$2245 for total healthcare charges if
all thepatientswere treatedwith FP 44mcg.These costs
savings suggest that decisions to select an inhaled corti-
costeroidbased solelyon the acquisition costsmayresult
in higher asthma care costs as well as total health care
costs. These ¢ndings are consistent with other studies
that restricting formularies to older drug technologies
as a cost savingsmeasuremay actually result in increased
overall costs to a health plan (30^31).
The results of this study add further evidence to
support the EPR 2 recommendations that lower micro-
gram doses of FP may produce the same or greater ben-
e¢t than other inhaled corticosteroids at comparable
doses. In addition, the superior e⁄cacy of FP compared
to other ICS observed in clinical trials is con¢rmedwith
the lower costs for FP in this analysis, and supports the
use of FP 44mcg over other ICS in patients who were
previously on short-acting b-agonists alone. These data
suggest that FP should be considered as the initial in-
haled corticosteroid for asthma controller therapy be-
cause of its greater cost-e¡ectiveness.
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